Table 1.
Vector | Age at vector administration | Quadriceps | Gastrocnemius | Diaphragm | Heart |
---|---|---|---|---|---|
AAV-SPhGAApA | 12 months | 33%* | 67% | 84% | 99% |
3 months 2 | 75% | 79% | 91% | 100% | |
AAV-MHCK7hGAApA | 12 months | 40%* | 28% | 48%* | 95% |
3 months 3 | 82% | 36% | 82% | 98% |
Reduction compared to sham-treated GAA-KO mice. Significant difference in older, versus younger, GAA-KO mice indicated
p<0.05.
Previously reported GAA-KO mice following administration of an equivalent number of AAV2/8 vector particles at 3 month of age [6].
Previously reported GAA-KO mice following administration of an equivalent number of AAV2/8 vector particles at 3 month of age [12].